Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.55
-0.0100-0.64%
Post-market: 1.580.0300+1.94%19:30 EDT
Volume:404.03K
Turnover:627.49K
Market Cap:69.83M
PE:-5.01
High:1.59
Open:1.57
Low:1.50
Close:1.56
52wk High:2.59
52wk Low:0.7006
Shares:45.05M
Float Shares:39.17M
Volume Ratio:0.73
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3096
EPS(LYR):-0.3161
ROE:-125.23%
ROA:-64.90%
PB:7.78
PE(LYR):-4.90

Loading ...

RenovoRx CEO Shaun Bagai presents at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026

Reuters
·
Jun 04

RenovoRx Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 01

RenovoRx says FDA grants orphan drug designation for oxaliplatin in pancreatic cancer

Reuters
·
May 28

RenovoRx - Odd Provides Seven Years of Market Exclusivity Upon FDA Approval

THOMSON REUTERS
·
May 28

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

THOMSON REUTERS
·
May 28

RenovoRx announces pharmacokinetic data using TAMP platform

TIPRANKS
·
May 26

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 26

RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery

Reuters
·
May 24

RenovoRx Insider Makes Bold Move With Fresh Share Purchase

TIPRANKS
·
May 22

RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690

Reuters
·
May 21

RenovoRx Earnings Call Signals Commercial Inflection

TIPRANKS
·
May 20

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

GlobeNewswire
·
May 19

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)

TIPRANKS
·
May 16

RenovoRx (RNXT) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 15

RenovoRx Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

TIPRANKS
·
May 15

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

TIPRANKS
·
May 15

RenovoRx Q1 net loss widens 45% to $3.52 million; revenue rises 186% to $563,000

Reuters
·
May 15

RenovoRx Q1 revenue rises as number of active cancer centers increase

Reuters
·
May 15

RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.

Benzinga Earnings
·
May 15